Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06188065Recruiting

Eosinopenia in Severe COPD Exacerbation

Role: collaborator

NCT04902573Completed

A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes

Role: lead

NCT06788613Not Yet Recruiting

Utilising Hull Lung Health Study Data to Investigate the Performance of TidalSense Diagnostic Algorithms to Identify COPD and Pre-COPD Among Participants in the FRONTIER Programme.

Role: lead

NCT03808402Completed

The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS

Role: lead

NCT04355546Completed

Non-interventional Study Related to Fixed LAMA/LABA/ICS Triple Therapy

Role: lead

NCT03842904Phase 4Completed

A Study Comparing the Effects of Trimbow to Fostair in COPD

Role: collaborator

All 6 trials loaded